Previous 10 | Next 10 |
home / stock / vivxf / vivxf news
2023-03-17 08:32:08 ET Avivagen press release ( OTCPK:VIVXF ): Q1 GAAP EPS of -C$0.01. Revenue of C$0.07M (-74.1% Y/Y). For further details see: Avivagen GAAP EPS of -$0.01, revenue of $0.07M
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health ...
-Publication showcases the cumulative understanding to-date of Avivagen’s product from both a scientific and real world application perspective -Product’s value and safety has been shown through use in many settings, under differing conditions and in millions of animals ...
Avivagen Inc. (TSXV:VIV) (“ Avivagen ” or the “ Company ”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting...
Avivagen press release ( OTCQB:VIVXF ): Q3 Comprehensive loss of C$1.90M Revenue of C$48.61K (-94.5% Y/Y). For further details see: Avivagen reports Q3 results
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...
Publication of this Scientific Paper on the Safety of Oxidized Beta Carotene is a milestone on the path to broader regulatory clearance to market and sell OxC-beta ™ Products in the U.S. and supports wide-spread adoption of the technology around the world ...
*Family-owned dairy business with established reputation for high-quality products turning to OxC-beta™ to support quality of milk * Order procured through Meyenberg International, Avivagen’s Mexican distribution partner Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ...
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting gener...
A Pathway Into Brazil. Avivagen's management announced Wednesday that the Company has received a 1.2 tonne order of OxC-beta from AB Vista that will be shipped for use in Brazil. It will be used for ongoing trials with several large poultry and cattle producers. We believe that this is a stepp...
News, Short Squeeze, Breakout and More Instantly...
Avivagen Company Name:
VIVXF Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
Ottawa, Ontario--(Newsfile Corp. - April 24, 2024) - Avivagen Inc. (TSXV: VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance feed intake and support immune fu...
ManpowerGroup (MAN) is expected to report $0.89 for Q1 2024 West Coast Community Bancorp Com (SCZC) is expected to report for Q1 2024 BayCom Corp (BCML) is expected to report $0.56 for Q1 2024 Infosys Limited American Depositary Shares (INFY) is expected to report $0.17 for Q4 2024 ...